Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20522541 | 0.85 | MGLL (0.32) | KMT2AMGLLLMNASMN1; SMN2 | |
| SCHEMBL14860981 | 0.85 | MAPK1 (0.48) | MAPK1KMT2AMGLLTSHRALDH1A1 | |
| SCHEMBL747344 | 0.82 | ALDH1A1 (0.38) | MAPK1KMT2AMGLLALDH1A1LMNA | |
| SCHEMBL31474901 | 0.81 | MAPK1 (0.35) | MAPK1KMT2AMGLLALDH1A1NPSR1 | |
| SCHEMBL317623 | 0.81 | MAPK1 (0.35) | MAPK1KMT2AMGLLALDH1A1NPSR1 | |
| SCHEMBL31474902 | 0.81 | MAPK1 (0.35) | MAPK1KMT2AMGLLALDH1A1NPSR1 | |
| SCHEMBL31474903 | 0.81 | MAPK1 (0.35) | MAPK1KMT2AMGLLALDH1A1NPSR1 | |
| SCHEMBL4393639 | 0.81 | TSHR (0.45) | MAPK1KMT2AMGLLTSHRALDH1A1 | |
| SCHEMBL1696190 | 0.81 | NPC1 (0.47) | MAPK1KMT2AALDH1A1NPC1GAA | |
| SCHEMBL4897945 | 0.79 | CA12 (0.46) | MAPK1KMT2AMGLLALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1968651-A2 | STABILIZED COMPOSITIONS AND METHODS FOR RADIOLABELING PHARMACEUTICALS WITH ALPHA-PARTICLE EMITTERS | Duke University (US) | 2008-09-17 | — | — | EP | claimed |
| WO-2007120251-A2 | STABILIZED COMPOSITIONS AND METHODS FOR RADIOLABELING PHARMACEUTICALS WITH ALPHA-PARTICLE EMITTERS | DUKE UNIVERSITY (US) | 2007-10-25 | — | — | WO | claimed |
| EP-4151278-B1 | BIOTIN-MODIFIED DIMER AND USE THEREOF | UNIV TOKYO (JP) | 2026-05-13 | — | — | EP | disclosed |
| US-11851383-B2 | Automatic process platform for the production of astatine-211 [At-211]-radiopharmaceuticals | ALPHA THERAPY SOLUTIONS AB (SE) | 2023-12-26 | — | — | US | disclosed |
| US-20230241257-A1 | BIOTIN-MODIFIED DIMER AND USE THEREOF | THE UNIVERSITY OF TOKYO (JP) | 2023-08-03 | — | — | US | disclosed |
| CN-110072888-B | Pharmaceutical agents, uses and methods | H.隆德贝克有限公司 | 2023-07-18 | — | — | CN | disclosed |
| CN-110267985-B | Antibodies specific for hyperphosphorylated tau protein for the treatment of ophthalmic diseases | H.隆德贝克有限公司 | 2023-05-23 | — | — | CN | disclosed |
| CN-116041504-A | Antibodies specific for hyperphosphorylated tau and methods of use thereof | H.隆德贝克有限公司 | 2023-05-02 | — | — | CN | disclosed |
| CN-115925921-A | Agents, uses and methods for the treatment of synucleinopathies | H.隆德贝克有限公司 | 2023-04-07 | — | — | CN | disclosed |
| EP-4151278-A1 | BIOTIN-MODIFIED DIMER AND USE THEREOF | The University of Tokyo (JP) | 2023-03-22 | — | — | EP | disclosed |
| CN-109618556-B | Antibodies specific for hyperphosphorylated tau protein and methods of use thereof | H.隆德贝克有限公司 | 2022-10-21 | — | — | CN | disclosed |
| US-20110280803-A1 | RADIOIODINATION METHOD | GE HEALTHCARE UK LIMITED (GB) | 2011-11-17 | — | — | US | disclosed |
| EP-2382185-A1 | RADIOIODINATION METHOD | GE Healthcare Limited (GB) | 2011-11-02 | — | — | EP | disclosed |
| WO-2010086398-A1 | RADIOIODINATION METHOD | GE HEALTHCARE LIMITED (GB) | 2010-08-05 | — | — | WO | disclosed |
| US-20090304585-A1 | Stabilized Compositions and Methods for Radiolabeling Pharmaceuticals with Alpha-Particle Emitters | DUKE UNIVERSITY (US) | 2009-12-10 | — | — | US | disclosed |
| EP-1968651-A2 | STABILIZED COMPOSITIONS AND METHODS FOR RADIOLABELING PHARMACEUTICALS WITH ALPHA-PARTICLE EMITTERS | Duke University (US) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007120251-A2 | STABILIZED COMPOSITIONS AND METHODS FOR RADIOLABELING PHARMACEUTICALS WITH ALPHA-PARTICLE EMITTERS | DUKE UNIVERSITY (US) | 2007-10-25 | — | — | WO | disclosed |
| US-20060133994-A1 | Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis | NERI DARIO | 2006-06-22 | — | — | US | disclosed |
| EP-1259548-A1 | ANTIBODY SPECIFIC FOR THE ED-B DOMAIN OF FIBRONECTIN, CONJUGATES COMPRISING SAID ANTIBODY, AND THEIR USE FOR THE DETECTION AND TREATMENT OF ANGIOGENESIS | Eidgenössische Technische Hochschule Zürich (CH) | 2002-11-27 | — | — | EP | disclosed |
| WO-2001062800-A1 | ANTIBODY SPECIFIC FOR THE ED-B DOMAIN OF FIBRONECTIN, CONJUGATES COMPRISING SAID ANTIBODY, AND THEIR USE FOR THE DETECTION AND TREATMENT OF ANGIOGENESIS | Eidgenössische Technische Hochschule Zürich (CH) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110280803-A1 | RADIOIODINATION METHOD | TPO, SSTR5, DAO | MAPK1 4089/4885KMT2A 287/4885MGLL 3806/4885 |
| US-20230241257-A1 | BIOTIN-MODIFIED DIMER AND USE THEREOF | BTD, HLCS, BRD4 | MAPK1 3629/4885KMT2A 2351/4885MGLL 4592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.